SWOG is a research organization with cancer investigators distributed across 550 academic and community sites throughout the U.S. Canada, Latin America, Korea, and Saudi Arabia. The Group has a long history of conducting clinical trials that have changed standard of oncologic practice and that have led to Food and Drug Administration approval of new anti-neoplastic agents. SWOG's mission is to design, direct and participate in clinical trials that will result in effective prevention and treatment of cancer in the process improving quality of life and quality of survivorship for those with malignancies. Guiding principles used to help achieve these goals include placing patients as our highest priority, using the best science to drive our research, embracing diversity in membership and leadership, demanding ethical behavior, and fostering young investigators. SWOG's specific aims for this application include Improving efficiency and rapidly executing the clinical trial development and conduct processes; collaborating widely to reduce accrual barriers and facilitate participation in NCTN trials; maximizing potential from international partners by studying globally-significant cancers; and being active participants and leaders in NCTN management. Building on our successful past while significantly moving forward, SWOG will be a clinical trials organization dedicated to conducting high-value, high-impact cancer trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180888-02S2
Application #
9132524
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2015
Total Cost
$34,899
Indirect Cost
$6,500
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Othus, Megan; Sekeres, Mikkael A; Nand, Sucha et al. (2018) Relative survival following response to 7?+?3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia :
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888

Showing the most recent 10 out of 249 publications